Bristol Myers Squibb’s Liso-cel Shows High, Durable Responses in Relapsed/Refractory Marginal Zone Lymphoma

Jun 16 , 2025

PRINCETON, N.J. – Bristol Myers Squibb (NYSE: BMY) announced strong primary analysis results for its CAR T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel), in patients with relapsed or refractory marginal zone lymphoma (MZL). Data from the Phase 2 TRANSCEND FL study will be presented at the 2025 International Conference on Malignant Lymphoma (ICML).

In efficacy-evaluable patients (n=66), Breyanzi achieved a 95.5% overall response rate (ORR), with 62.1% achieving a complete response (CR). The therapy demonstrated remarkable durability, with 24-month rates of 88.6% for duration of response, 85.7% for progression-free survival, and 90.4% for overall survival.

Breyanzi maintained a consistent safety profile with low rates of severe cytokine release syndrome (CRS) and neurologic events (NE). This data highlights Breyanzi’s potential as a transformative, one-time treatment for this hard-to-treat blood cancer.

Source:

https://www.businesswire.com/news/home/20250613870408/en/Bristol-Myers-Squibb-Presents-First-Data-from-the-Marginal-Zone-Lymphoma-Cohort-of-the-Transcend-FL-Trial-Demonstrating-Deep-and-Durable-Responses-with-Breyanzi-lisocabtagene-maraleucel

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.